Teva upgraded to Neutral from Underweight at JPMorgan

JPMorgan analyst Chris Schott upgraded Teva Pharmaceutical to Neutral from Underweight with a $14 price target. Teva continues to progress its innovative pipeline, the analyst tells investors in a research note. The firm says that while it has been concerned the investments required to develop Teva’s assets would pressure margins, the company has done an effective job of partnering programs to address this dynamic. It sees a more balanced risk/reward at current share levels.